Pfizer's Trading Volume Surges 41.33% to $11.43 Billion, Ranks 78th in Market

On April 23, 2025, Pfizer's trading volume reached $11.43 billion, marking a significant increase of 41.33% compared to the previous day, placing it at the 78th position in the day's stock market rankings. Pfizer's stock price closed at $0.62% lower than the previous day.

Pfizer has announced that it will be conducting a clinical trial for its new drug, which is designed to treat a rare genetic disorder. The trial will involve 500 patients and is expected to last for two years. The company has stated that the results of the trial will be crucial in determining the drug's efficacy and safety.

Pfizer has also announced that it will be expanding its manufacturing capabilities in the United States. The company plans to invest $1 billion in a new manufacturing facility in North Carolina, which will create 500 new jobs. The facility is expected to be operational by the end of 2026.

Pfizer has also announced that it will be acquiring a biotechnology company, which specializes in the development of gene therapies. The acquisition is expected to be completed by the end of the year, and the terms of the deal have not been disclosed. The acquisition is part of Pfizer's strategy to expand its portfolio of innovative therapies.